Bluebird Confident In Financial Runway For Skysona Launch
No Outcomes-Based Agreements Planned
The $3m gene therapy for the rare disease cerebral adrenoleukodystrophy marks bluebird’s second approval in just under a month.
The $3m gene therapy for the rare disease cerebral adrenoleukodystrophy marks bluebird’s second approval in just under a month.